These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 29108908)

  • 21. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
    Liu LY; King BA
    J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S18-S20. PubMed ID: 29273099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ruxolitinib for the treatment of severe alopecia areata.
    Liu LY; King BA
    J Am Acad Dermatol; 2019 Feb; 80(2):566-568. PubMed ID: 30195572
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopecia areata and variants: a double-blind, randomized controlled trial.
    Paracha M; Wasim M; Noor SM; Khan AQ; Sagheer F; Ahmad I
    Arch Dermatol Res; 2024 Jul; 316(7):458. PubMed ID: 38967866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
    Salman A; Sarac G; Ergun T
    Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Excellent response to tofacitinib treatment in a patient with alopecia universalis.
    Erduran F; Adışen E; Aksakal AB
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):47-49. PubMed ID: 28632888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tofacitinib].
    Döker S; Dewenter M; El-Armouche A
    Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Alopecia areata with good response to tofacitinib].
    Maksimow A; Stintzing D; Wohlrab J
    Hautarzt; 2021 Jun; 72(6):525-527. PubMed ID: 33044559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
    Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
    JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis.
    Putterman E; Castelo-Soccio L
    J Am Acad Dermatol; 2018 Jun; 78(6):1207-1209.e1. PubMed ID: 29754888
    [No Abstract]   [Full Text] [Related]  

  • 31. Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life.
    Liu LY; Craiglow BG; King BA
    J Am Acad Dermatol; 2018 Mar; 78(3):597-599.e2. PubMed ID: 29128459
    [No Abstract]   [Full Text] [Related]  

  • 32. Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
    Noell C; Arbeit R; Kanhoush R
    Dermatol Online J; 2018 Jan; 24(1):. PubMed ID: 29469766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tofacitinib for the treatment of alopecia areata in preadolescent children.
    Craiglow BG; King BA
    J Am Acad Dermatol; 2019 Feb; 80(2):568-570. PubMed ID: 30195571
    [No Abstract]   [Full Text] [Related]  

  • 34. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis.
    Guo L; Feng S; Sun B; Jiang X; Liu Y
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):192-201. PubMed ID: 31494993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
    Sonomoto K; Tanaka Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Case Report Highlighting the Effective Treatment of Alopecia Universalis With Tofacitinib in an Adolescent and Adult Patient.
    Patel NU; Oussedik E; Grammenos A; Pichardo-Geisinger R
    J Cutan Med Surg; 2018; 22(4):439-442. PubMed ID: 29463114
    [No Abstract]   [Full Text] [Related]  

  • 37. Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata.
    Akdogan N; Ersoy-Evans S; Doğan S; Atakan N
    Dermatol Ther; 2019 Nov; 32(6):e13118. PubMed ID: 31621150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
    Mamolo C; Harness J; Tan H; Menter A
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Janus kinase inhibitors in dermatology: A systematic review.
    Shreberk-Hassidim R; Ramot Y; Zlotogorski A
    J Am Acad Dermatol; 2017 Apr; 76(4):745-753.e19. PubMed ID: 28169015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
    Di Lernia V; Bardazzi F
    Drug Des Devel Ther; 2016; 10():533-9. PubMed ID: 26889081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.